Abstract
Histopathology and immunohistochemistry continue to be popular methods for predicting outcome in patients with malignant gliomas. This past year traditional histopathologic studies have stressed the importance of endothelial proliferation in the diagnosis of glioblastoma multiforme. Immunohistochemical proliferation markers, in particular MIB-1, may be useful in assessing oligodendroglioma behavior, whereas their role in malignant astrocytomas is less clear. Similarly, new studies on p53 and epidermal growth factor receptor immunohistochemistry in gliomas have demonstrated only limited predictive values.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have